Total Payments
$672,005
2024 Payments
$153,406
Companies
23
Transactions
351
Medicare Patients
138
Medicare Billing
$16,213
Payment Breakdown by Category
Consulting$505,440 (75.2%)
Travel$89,009 (13.2%)
Research$63,125 (9.4%)
Other$7,635 (1.1%)
Food & Beverage$6,797 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $505,440 | 122 | 75.2% |
| Travel and Lodging | $89,009 | 103 | 13.2% |
| Unspecified | $63,125 | 22 | 9.4% |
| Food and Beverage | $6,797 | 102 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 1 | 0.9% |
| Honoraria | $1,635 | 1 | 0.2% |
Payments by Type
General
$608,880
329 transactions
Research
$63,125
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $152,436 | 45 | $0 (2024) |
| Novo Nordisk AS | $103,979 | 30 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $75,302 | 31 | $0 (2021) |
| Amarin Pharma Inc. | $61,024 | 53 | $0 (2020) |
| Novo Nordisk Inc | $48,678 | 20 | $0 (2022) |
| Esperion Therapeutics, Inc. | $36,411 | 2 | $0 (2021) |
| Amgen Inc. | $35,452 | 37 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29,927 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $28,907 | 22 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $21,028 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $153,406 | 52 | Eli Lilly and Company ($115,138) |
| 2023 | $79,348 | 47 | Novo Nordisk AS ($27,725) |
| 2022 | $90,937 | 37 | Novo Nordisk AS ($62,679) |
| 2021 | $84,409 | 35 | Esperion Therapeutics, Inc. ($36,411) |
| 2020 | $77,730 | 37 | Amarin Pharma Inc. ($31,075) |
| 2019 | $84,858 | 70 | SANOFI-AVENTIS U.S. LLC ($33,999) |
| 2018 | $90,499 | 60 | SANOFI-AVENTIS U.S. LLC ($35,781) |
| 2017 | $10,817 | 13 | Amgen Inc. ($5,600) |
All Payment Transactions
351 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $3,016.00 | General |
| Category: Cardiology | ||||||
| 12/24/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $2,975.00 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $391.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $379.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $379.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/26/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,880.00 | General |
| 11/26/2024 | Genentech, Inc. | — | Food and Beverage | Cash or cash equivalent | $47.99 | General |
| 11/26/2024 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $44.00 | General |
| 11/25/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $45,500.00 | General |
| 11/21/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 11/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $5,744.20 | General |
| 11/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $157.40 | General |
| 11/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $144.12 | General |
| 11/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $144.12 | General |
| 11/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $123.90 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $149.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $538.03 | General |
| 11/05/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $157.40 | General |
| 11/04/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $123.90 | General |
| 10/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $391.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $379.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $379.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/25/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $9,548.80 | General |
| 09/25/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $457.92 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT | Esperion Therapeutics, Inc. | $36,390 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,180 | 2 |
| Prospective Observational study of Lipid Management in Non-US, Non-Western European Patients Who Have A Recent Acute Coronary Syndrome Event | SANOFI-AVENTIS U.S. LLC | $1,250 | 1 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $1,110 | 1 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO PRALUENT | Regeneron Pharmaceuticals, Inc. | $944.13 | 3 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $35.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 13 | 15 | $6,960 | $2,088 |
| 2020 | 6 | 125 | 171 | $47,558 | $14,125 |
Total Patients
138
Total Services
186
Medicare Billing
$16,213
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 15 | $6,960 | $2,088 | 30.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 53 | $13,250 | $4,246 | 32.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 17 | $8,262 | $2,515 | 30.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 24 | 28 | $9,632 | $2,297 | 23.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 22 | 23 | $6,256 | $1,907 | 30.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 32 | $5,568 | $1,810 | 32.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 18 | $4,590 | $1,349 | 29.4% |
About Ann Navar, MD, PHD
Ann Navar, MD, PHD is a Cardiovascular Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2009. The National Provider Identifier (NPI) number assigned to this provider is 1609018639.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ann Navar, MD, PHD has received a total of $672,005 in payments from pharmaceutical and medical device companies, with $153,406 received in 2024. These payments were reported across 351 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($505,440).
As a Medicare-enrolled provider, Navar has provided services to 138 Medicare beneficiaries, totaling 186 services with total Medicare billing of $16,213. Data is available for 2 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Dallas, TX
- Active Since 04/06/2009
- Last Updated 09/24/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1609018639
Products in Payments
- Vascepa (Drug) $61,024
- NO PRODUCT DISCUSSED (Drug) $43,669
- NEXLETOL (Drug) $36,411
- Repatha (Biological) $31,812
- PRALUENT (Drug) $30,359
- Kerendia (Drug) $26,737
- Victoza (Drug) $18,607
- LEQVIO (Drug) $17,853
- BRILINTA (Drug) $15,392
- JARDIANCE (Drug) $14,940
- PRALUENT (Biological) $11,319
- PRALUENT ALIROCUMAB INJECTION (Biological) $10,960
- ELIQUIS (Drug) $7,479
- Non-Covered $2,170
- EPANOVA (Drug) $1,992
- XARELTO (Drug) $255.66
- Ozempic (Drug) $105.49
- LifeVest (Device) $99.75
- GENERAL PAIN MANAGEMENT (Device) $97.78
- EVENITY (Biological) $30.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Dallas
Darren Mcguire, Md, MD
Cardiovascular Disease — Payments: $2.0M
Cardiovascular Disease $2.0M
Dr. Peter Mccullough, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Robert Stoler, M.d, M.D
Cardiovascular Disease — Payments: $719,078
Cardiovascular Disease $719,078
Martin Berk, M.d, M.D
Cardiovascular Disease — Payments: $493,450
Cardiovascular Disease $493,450
James De Lemos, Md, MD
Cardiovascular Disease — Payments: $448,409
Cardiovascular Disease $448,409
Eric Peterson, M.d, M.D
Cardiovascular Disease — Payments: $404,014
Cardiovascular Disease $404,014